IPPRA / Grant Monitor

2026-07-07
← Board

Development of Biomarkers or Composite Biomarkers for Neurological and Neuromuscular Disorders (R61/R33 - Clinical Trial Optional)

PAR-25-024 · National Institutes of Health

biomedical clinical public health ai data science Health

Closes
2028-01-07 · 549 d
Award ceiling
Award floor
Program funding
Expected awards
Cost sharing
No
Posted
2024-10-28
Instrument
Grant
Characterization · gpt-5.4-mini · 2026-07-07

NIH funds discovery and early evaluation of candidate biomarkers or biomarker signatures for neurological and neuromuscular disorders, including required preliminary human sample or dataset evaluation, to support later clinical validation.

Funds
applied research
University
direct
social behavioral
minor
physical sciences
minor
engineering
minor
life biomedical
central
computational data
substantial

⚑ Clinical Trial Optional. · Non-domestic (non-U.S.) entities are not eligible; non-domestic components of U.S. organizations are also not eligible.

Unit fits — one characterization, each unit's own rules

Physical Sciences & Engineering (demo) 80 strong technical depth: substantial; funds applied research
IPPRA 58 good peripheral portfolio topic: public_health; social/behavioral work is minor; funds applied research; biomedical core — IPPRA health lane is communication/crisis/policy (capped); clinical-trial/biomedical core — IPPRA angle is policy/community (capped)
Tom Love Innovation Hub 30 weak funds applied research; deep-tech content

Description

The overarching purpose of this Funding Opportunity Announcement (FOA) is to promote the discovery and/or early evaluation of strong candidate biomarkers and biomarker signatures that can be used as tools to facilitate the clinical development of neurotherapeutics and their use in clinical practice. Specifically, the focus of this FOA is on the identification and initial biological, analytical and clinical evaluation of biomarkers and biomarker signatures for neurological and neuromuscular disorders. Although research supported by this FOA can include animal studies, it must also include preliminary human evaluation using carefully standardized human samples or datasets. The goal of this initiative is to deliver candidate biomarkers or biomarker signatures that are ready for definitive analytical and clinical validation studies.

Eligibility

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.

Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.

Apply

View on Grants.gov → CONTACT: National Institutes of Health <grantsinfo@nih.gov>

Proposal brief SEE AN EXAMPLE →

A one-page internal memo: fit assessment, submission requirements, document scaffold, and next steps dated back from the deadline — tailored to your project idea if you add one.

ONE LLM CALL (~1¢) · CACHED · REQUIRES STAFF KEY

Proposal shell · National Institutes of Health conventions SEE AN NIH EXAMPLE →

Funder-faithful document skeletons — National Institutes of Health's document set with section headings, page limits, reviewer guidance, and writing prompts; add a project idea to get [DRAFT] starter bullets. Download as .md for Word or Overleaf.

ONE LLM CALL (~2-3¢) · CACHED · SCAFFOLDING, NOT GHOSTWRITING